Welcome to our dedicated page for Cassava Sciences SEC filings (Ticker: SAVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cassava Sciences, Inc. (NASDAQ: SAVA) SEC filings page on Stock Titan aggregates the company’s official U.S. Securities and Exchange Commission disclosures, giving investors structured access to its regulatory record. Cassava is a clinical-stage biotechnology company based in Austin, Texas that focuses on developing simufilam, a proprietary, investigational oral small molecule for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy.
Through this page, readers can review Form 8-K current reports in which Cassava describes material events. Recent 8-K filings detail topics such as a binding term sheet to settle a consolidated securities class action for $31.25 million, the FDA’s decision to place the proposed proof-of-concept clinical trial of simufilam in TSC-related epilepsy on full clinical hold pending additional preclinical data and protocol modifications, and the dismissal of a criminal indictment against a former scientific collaborator. Other 8-Ks furnish earnings press releases, corporate presentations, and announcements regarding board appointments and executive compensation decisions tied to development and budgeting goals.
Investors can also connect these current reports with Cassava’s periodic filings, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which the company references in its risk factor and forward-looking statement discussions. These documents provide broader context on research and development spending, general and administrative expenses, cash and cash equivalents, and recorded loss contingencies related to securities litigation and regulatory matters.
Stock Titan’s platform supplements this raw filing data with AI-powered summaries that highlight the key points in lengthy documents, helping users quickly identify items related to clinical holds, settlement agreements, program discontinuations, and changes in leadership or governance. For those monitoring insider activity, real-time access to Form 4 insider transaction reports and other ownership-related filings is available, allowing a detailed view of equity movements by officers and directors alongside the company’s broader regulatory history.
Cassava Sciences, Inc. filed a current report to furnish its latest corporate presentation under Regulation FD. The presentation, dated September 2025, is made available as Exhibit 99.1 and is also posted in the Investors section of the company’s website. The company states that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and will not be automatically incorporated into other securities law filings.
Cassava Sciences reported a net loss of $44.2 million for the quarter and $67.6 million for the six months ended June 30, 2025, driven by $40.3 million of general and administrative expense and $5.1 million of research and development expense in the quarter. Cash and cash equivalents totaled $112.4 million, down from $128.6 million at year-end 2024, while total assets fell to $135.4 million and stockholders' equity declined to $88.0 million. Accounts payable and accrued expenses increased materially to $42.8 million, contributing to total liabilities of $47.4 million.
The company recorded $35.25 million of litigation loss contingencies as of June 30, 2025, including a $31.25 million reserve related to the consolidated securities action and a $4.0 million reserve related to an anti-SLAPP matter. Cassava paid a $40 million civil penalty to settle an SEC enforcement matter in 2024 and continues to cooperate with DOJ inquiries. Management states working capital is sufficient for at least the next 12 months. Operationally, the company completed the phase-out of its Alzheimer’s program in Q2 2025, entered a Yale license for simufilam in TSC-related epilepsy with up to $4.5 million in milestones plus tiered royalties, and announced positive preclinical TSC results showing a dose-related reduction in seizures in a mouse model.
Cassava Sciences, Inc. furnished an 8-K related to its results of operations and financial condition. On August 14, 2025, the company issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The press release contains the detailed financial and operating information.
The company specifies that the information in this report, including Exhibit 99.1, is being furnished and not filed under the Securities Exchange Act of 1934, which limits its use for certain legal liability purposes and for incorporation by reference into other securities filings.
Cassava Sciences (SAVA) filed an 8-K to disclose positive preclinical data for simufilam in tuberous sclerosis complex (TSC)-related epilepsy. In a Tsc1 conditional knockout mouse model that develops spontaneous seizures, multiple doses of simufilam were tested over ~3 weeks. The compound significantly reduced seizure progression in a dose-dependent manner; other measured endpoints did not reach significance.
The study was run with the TSC Alliance and PsychoGenics under the TSC Preclinical Consortium. Management plans to present full data at a scientific meeting and initiate the first human proof-of-concept trial in H1 2026. No financial terms, revenue impact, or guidance were provided. Item 7.01 makes the accompanying press release furnished, not filed.
Key takeaways:
- Preclinical efficacy signal supports simufilam’s mechanism beyond Alzheimer’s.
- Expands pipeline into rare-disease epilepsy market.
- Tight timeline sets a near-term catalyst but still carries high development risk.